scholarly journals Combined evaluation of a panel of protein and miRNA serum-exosome biomarkers for pancreatic cancer diagnosis increases sensitivity and specificity

2014 ◽  
Vol 136 (11) ◽  
pp. 2616-2627 ◽  
Author(s):  
Bindhu Madhavan ◽  
Shijing Yue ◽  
Uwe Galli ◽  
Sanyukta Rana ◽  
Wolfgang Gross ◽  
...  
Keyword(s):  
Pancreatic Cancer ◽  
Sensitivity And Specificity ◽  
Cancer Diagnosis ◽  
Combined Evaluation

Combined Evaluation of Serum Ribonuclease and Ferritin: Any Advantages in Pancreatic Cancer Diagnosis?

Oncology ◽  
1984 ◽  
Vol 41 (6) ◽  
pp. 393-395 ◽  
Author(s):  
C. Fabris ◽  
R. Farini ◽  
G.D. Del Favero ◽  
F. Grassi ◽  
D. Nitti ◽  
...  
Keyword(s):  
Pancreatic Cancer ◽  
Cancer Diagnosis ◽  
Combined Evaluation ◽  
Serum Ribonuclease

Extracellular Vesicles in Tumor Diagnosis: A Mini-Review

2020 ◽  
Vol 20 ◽  
Author(s):  
Si Yu ◽  
Menglin Huang ◽  
Jingyu Wang ◽  
Yongchang Zheng ◽  
Haifeng Xu
Keyword(s):  
Clinical Diagnosis ◽  
Sensitivity And Specificity ◽  
Cancer Diagnosis ◽  
Cancer Biomarkers ◽  
Related Substances ◽  
Physiological Processes ◽  
Cancer Pathogenesis ◽  
Limited Application ◽  
Low Sensitivity ◽  
Shed Light

: Widely exploration of noninvasive tumor/cancer biomarkers has shed light on clinical diagnosis. However, many under-investigated biomarkers showed limited application potency due to low sensitivity and specificity, while extracellular vehicles (EVs) were gradually recognized as promising candidates. EVs are small vesicles transporting bioactive cargos between cells in multiple physiological processes and also in tumor/cancer pathogenesis. This review aimed to offer recent studies of EVs on structure, classification, physiological functions, as well as changes in tumor initiation and progression. Furthermore, we focused on advances of EVs and/or EV-related substances in cancer diagnosis, and summarized ongoing studies of promising candidates for future investigations.

Molecular markers in pancreatic cancer diagnosis

2013 ◽  
Vol 418 ◽  
pp. 22-29 ◽  
Author(s):  
Marta Herreros-Villanueva ◽  
Meritxel Gironella ◽  
Antoni Castells ◽  
Luis Bujanda
Keyword(s):  
Pancreatic Cancer ◽  
Molecular Markers ◽  
Cancer Diagnosis

scholarly journals Correction: The Association of Statin Use after Cancer Diagnosis with Survival in Pancreatic Cancer Patients: A SEER-Medicare Analysis

PLoS ONE ◽  
2015 ◽  
Vol 10 (5) ◽  
pp. e0128730 ◽  
Author(s):  
Christie Y. Jeon ◽  
Stephen J. Pandol ◽  
Bechien Wu ◽  
Galen Cook-Wiens ◽  
Roberta A. Gottlieb ◽  
...  
Keyword(s):  
Pancreatic Cancer ◽  
Cancer Patients ◽  
Cancer Diagnosis ◽  
After Cancer ◽  
Statin Use

scholarly journals Towards pancreatic cancer diagnosis using EIS biochips

Lab on a Chip ◽  
2013 ◽  
Vol 13 (4) ◽  
pp. 730 ◽  
Author(s):  
Maria Serena Chiriacò ◽  
Elisabetta Primiceri ◽  
Anna Grazia Monteduro ◽  
Anna Bove ◽  
Stefano Leporatti ◽  
...  
Keyword(s):  
Pancreatic Cancer ◽  
Cancer Diagnosis

scholarly journals Advance in Pancreatic Cancer Diagnosis and Therapy

2020 ◽  
Author(s):  
Xiaojie Cai ◽  
Jie Gao ◽  
Yanfang Liu ◽  
Ming Wang ◽  
Qiulian Ma ◽  
...  
Keyword(s):  
Pancreatic Cancer ◽  
Stem Cells ◽  
Survival Rate ◽  
Tumor Microenvironment ◽  
Cancer Diagnosis ◽  
Treatment Resistance ◽  
Serum Markers ◽  
Molecular Probes ◽  
Cancer Death ◽  
Cancer Diagnosis And Therapy

Pancreatic carcinoma is the fourth leading cause of cancer death in the word wild. Although the advance in treatment this disease, the 5-years survival rate is still rather low. In the recent year, many new therapy and treatment avenues have been developed for pancreatic cancer. In this chapter, we mainly focus on the following aspect: 1) the treatment modality in pancreatic cancer, including chemotherapy, radiotherapy, and immunotherapy; 2) the mechanism of pancreatic cancer treatment resistance, especially in cancer stem cells and tumor microenvironment; 3) the diagnosis tools in pancreatic cancer, including serum markers, imaging methods and endoscopic ultrasonography. Novel molecular probes based on the nanotechnology in the diagnosis of pancreatic cancer are also discussed.

Cancer Survival Is (Mostly) Improving

Pained ◽  
2020 ◽  
pp. 245-246
Author(s):  
Michael D. Stein ◽  
Sandro Galea
Keyword(s):  
Prostate Cancer ◽  
United States ◽  
Pancreatic Cancer ◽  
Survival Rate ◽  
Cancer Diagnosis ◽  
Cancer Survival ◽  
Prostate Cancer Screening ◽  
Survival Rates ◽  
The United States ◽  
Cervical Cancers

This chapter discusses how the 5-year survival rates for the most common cancers in the United States improved by nearly 20% since the 1970s. While promising overall, low survival rates persist for pancreatic, liver, lung, esophageal, brain, and many other cancers. Meanwhile, 5-year survival for uterine and cervical cancers worsened. Pancreatic cancer has the lowest 5-year survival rate at 8.2%. In contrast, prostate cancer had the greatest 5-year survival increase from 67.8% to 98.6%, most likely reflecting a substantial uptick in prostate cancer screening and early detection. Five-year survival with leukemia also improved significantly, from 34.2% to 60.6%, likely resulting from improved treatments. As such, in both detection and treatment, the United States is making progress. For the millions of Americans who face a cancer diagnosis, this is cause for hope.

Impact of Pancreatic Cancer and Subsequent Resection on Glycemic Control in Diabetic and Nondiabetic Patients

2011 ◽  
Vol 77 (8) ◽  
pp. 1032-1037 ◽  
Author(s):  
Michael A. White ◽  
Steven C. Agle ◽  
Hannah M. Fuhr ◽  
James H. Mehaffey ◽  
Brett H. Waibel ◽  
...  
Keyword(s):  
Pancreatic Cancer ◽  
Glycemic Control ◽  
Cancer Diagnosis ◽  
Univariate Analysis ◽  
Cell Mass ◽  
University Teaching ◽  
Partial Pancreatectomy ◽  
Onset Diabetes ◽  
Number Of Factors ◽  
New Onset

The incidence of new onset or worsening diabetes is surprisingly low in patients after partial pancreatectomy for cancer, leading us to question what factors predict diminished glycemic control in those undergoing resection. All patients undergoing pancreatectomy for cancer at a large, rural university teaching hospital between 1996 and 2010 were identified. The incidence of new onset, or worsening, existing diabetes was determined based on pre and postoperative medication requirement. Univariate analysis was undertaken to identify factors that predict worsened glycemic control. One hundred and one (1 total, 79 Whipple, 21 distal) patients were identified, 41 per cent of which had preexisting diabetes. Nearly half of existing diabetics manifested an increased medication requirement prior to their cancer diagnosis. New onset diabetes occurred in 20 per cent of postoperative patients. Of established diabetics, 34 per cent had either improved glycemic control (9/41) or were cured (5/41) despite the reduction of islet cell mass that occurred with surgery. On univariate analysis, only prolonged hospitalization was associated with worsened glycemic control. Diminished glycemic control is a frequent presenting symptom of pancreatic cancer. Worsened or new onset diabetes is associated with length of stay, which can be influenced by a number of factors including complications and comorbidities.

Sign in / Sign up

Export Citation Format

Share Document